Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Immune MAL2-practice: breast cancer immunoevasion via MHC class I degradation

Journal of Clinical Investigation(2021)10.1172/jci144344Source: DataRank Database

Immune MAL2-practice: breast cancer immunoevasion via MHC class I degradation is a research paper published in Journal of Clinical Investigation (2021). On theSindex it has a DataRank of 0. It has been cited 49 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access49 citations

Download PDF

Cite:

Linked data & code

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:OA: bronzeTopics (16)Linked Datasets (25)DataCite Reuse (25)IDs (PubMed, PMC)

FAIR Checklist

Context only (not used in score)

Findable (2/2)

Has DOI
Indexed in repositories

Accessible (1/2)

Open Access

Interoperable (2/2)

DataCite relations
Linked datasets

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (2)

Jonathan W. Yewdell ORCID,Devin Dersh ORCID

Live enrichment

PubMed:33393509 PMC:PMC7773378

bronze

publisherhttp://www.jci.org/articles/view/144344/files/pdf

publisherhttps://www.jci.org/articles/view/144344/files/pdf

repositoryhttps://www.ncbi.nlm.nih.gov/pmc/articles/7773378

Fields of Study

Antigens, NeoplasmBreast NeoplasmsCD8-Positive T-LymphocytesFemaleHistocompatibility Antigens Class IHumansImmunotherapyMyelin and Lymphocyte-Associated Proteolipid Proteins

MeSH Terms

CD8-Positive T-LymphocytesHumansBreast NeoplasmsAntigens, NeoplasmHistocompatibility Antigens Class IImmunotherapyFemaleMyelin and Lymphocyte-Associated Proteolipid Proteins

Additional file 1 of Targeting KK-LC-1 inhibits malignant biological behaviors of triple-negative breast cancer

10.6084/m9.figshare.22621210.v1figshare

Additional file 1 of Targeting KK-LC-1 inhibits malignant biological behaviors of triple-negative breast cancer

10.6084/m9.figshare.22621210figshare

Additional file 7 of Targeting KK-LC-1 inhibits malignant biological behaviors of triple-negative breast cancer

10.6084/m9.figshare.22621240figshare

Additional file 5 of Targeting KK-LC-1 inhibits malignant biological behaviors of triple-negative breast cancer

10.6084/m9.figshare.22621231figshare

Additional file 4 of Targeting KK-LC-1 inhibits malignant biological behaviors of triple-negative breast cancer

10.6084/m9.figshare.22621225figshare

Additional file 3 of Targeting KK-LC-1 inhibits malignant biological behaviors of triple-negative breast cancer

10.6084/m9.figshare.22621219figshare

Additional file 2 of Targeting KK-LC-1 inhibits malignant biological behaviors of triple-negative breast cancer

10.6084/m9.figshare.22621213.v1figshare

Additional file 15 of Targeting KK-LC-1 inhibits malignant biological behaviors of triple-negative breast cancer

10.6084/m9.figshare.22621270.v1figshare

Additional file 11 of Targeting KK-LC-1 inhibits malignant biological behaviors of triple-negative breast cancer

10.6084/m9.figshare.22621258figshare

Additional file 7 of Targeting KK-LC-1 inhibits malignant biological behaviors of triple-negative breast cancer

10.6084/m9.figshare.22621240.v1figshare

Additional file 9 of Targeting KK-LC-1 inhibits malignant biological behaviors of triple-negative breast cancer

10.6084/m9.figshare.22621249figshare

Additional file 10 of Targeting KK-LC-1 inhibits malignant biological behaviors of triple-negative breast cancer

10.6084/m9.figshare.22621255.v1figshare

Additional file 14 of Targeting KK-LC-1 inhibits malignant biological behaviors of triple-negative breast cancer

10.6084/m9.figshare.22621267figshare

Additional file 14 of Targeting KK-LC-1 inhibits malignant biological behaviors of triple-negative breast cancer

10.6084/m9.figshare.22621267.v1figshare

Additional file 3 of Targeting KK-LC-1 inhibits malignant biological behaviors of triple-negative breast cancer

10.6084/m9.figshare.22621219.v1figshare

Additional file 15 of Targeting KK-LC-1 inhibits malignant biological behaviors of triple-negative breast cancer

10.6084/m9.figshare.22621270figshare

Additional file 11 of Targeting KK-LC-1 inhibits malignant biological behaviors of triple-negative breast cancer

10.6084/m9.figshare.22621258.v1figshare

Additional file 13 of Targeting KK-LC-1 inhibits malignant biological behaviors of triple-negative breast cancer

10.6084/m9.figshare.22621264.v1figshare

Additional file 2 of Targeting KK-LC-1 inhibits malignant biological behaviors of triple-negative breast cancer

10.6084/m9.figshare.22621213figshare

Additional file 9 of Targeting KK-LC-1 inhibits malignant biological behaviors of triple-negative breast cancer

10.6084/m9.figshare.22621249.v1figshare